CCR7 and B-cell chronic lymphocytic leukemia: Cuesta-Mateos et al. [37] demonstrated that anti-CCR7 monoclonal antibodies can preserve T cell subsets while effectively removing tumor cells through a complement-mediated mechanism of action in chronic lymphocytic leukemia (CLL).